Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (480)	1/29/1999 8:45:00 AM
From: Anthony Wong	Respond to of 642

FOCUS-Prozac sales spur Eli Lilly fourth quarter Friday January 29, 2:10 am Eastern Time biz.yahoo.com Excerpts: Golden said the company is increasing its sales force, adding 100 people to its neurosciences unit, primarily selling Zyprexa and blockbuster Prozac drug, and 510 to sell its diabetes drugs. Lilly is in a partnership with Takeda Chemical Industries Ltd. , which recently filed a new drug application with the U.S. Food and Drug Administration for the diabetes drug ACTOS. Zyprexa sales made the biggest gain in the year, nearly doubling to $1.44 billion. Sales of Evista, which hit the U.S. market in January 1998, were $144 million. In December, the FDA granted Lilly permission to include on the Evista label that there is a lower incidence of breast cancer in post-menopausal women taking the drug.

To: Anthony Wong who wrote (480)	1/29/1999 8:48:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 642

Comments on LLY's earnings from labpuppy.com: Eli Lilly (LLY) reported $0.50 versus street expectations of $0.51 for the quarter. During the conference call, the company mentioned that it is comfortable with analyst expectations for 1999. The company announced a $1 billion share repurchase program. Prozac sales rose by only 8% but the company's newer products (such as Zyprexa, Evista, Gemzar, Reopro, etc.) performed better. The company is trying to expand its Prozac franchise through once-a-week formulations, a deal with Sepracor (SEPR) for an ‘improved" version of Prozac, combining Prozac with Zyprexa, etc. An interesting tidbit is that the preliminary safety data on its new diabetes drug, Actos (developed by Takedo) looks promising. This product will eventually compete with Warner-Lambert's (WLA) Rezulin. labpuppy.com